Hexvix filed in 26 EU countries:
This article was originally published in Clinica
Executive Summary
A marketing application for PhotoCure's bladder cancer imaging agent, Hexvix, has been deemed fileable in 26 European countries, the Oslo, Norway firm has reported. Each country has committed to take a decision to recognise the application, which has already been approved in Sweden, within 90 days, the company said. National marketing authorisation in each country will be issued following the approval of the product information for doctors and patients in the local language. Hexvix is designed for use with cystoscopy.